相关实验视频

Updated: Jun 29, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

低分子量聚乙烯胺作为瘤向磁共振成像的宏分子对比剂

Guangkuo Liu^1,2, Xinxin Li^1,2, Xiaojie Liu²

¹Hubei Key Laboratory for Novel Reactor and Green Chemistry Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology Wuhan 430205 China.

|April 3, 2024

概括

一种新的宏分子对比剂 (CA) 显示了瘤向和成像能力的增强,用于早期癌症检测. 与现有的临床选择相比,这种新药显示出更高的性能,提供了更好的诊断潜力.

科学领域:

生物医学工程生物医学工程
材料科学材料科学材料科学
放射学放射学是一门学科.

背景情况:

宏分子对比剂 (CA) 提供优越的对比和瘤向能力,而不是小分子CA,这对于早期瘤检测至关重要.
现有的临床对比剂在癌症早期诊断方面的特异性和有效性有限.

研究的目的:

合成和评估一种新的宏分子对比剂,用于增强瘤向磁共振成像 (MRI).
评估与临床标准相比,开发的CA的对比能力,瘤积累和生物相容性.

主要方法:

使用循环德林结合的低分子量聚乙烯胺合成宏分子骨干.
通过宿主-客人相互作用,结合含有亚达曼坦和加多 (Gd) 酸盐的线性聚合物.
用叶酸功能化使用生物对等化学用于瘤特定向.

主要成果:

合成的CA,PC/Ad-PEG2000-PLL(DTPA-Gd) -FA,与Magnevist (r1 = 4.25 mM-1 s-1) 相比,呈现出明显更高的纵向放松率 (r1 = 11.62 mM-1 s-1).
在体内研究证实了瘤区域的有效积累和与Magnevist相比更明亮的成像.
组织学 (H&E染色) 和代谢分析表明了极好的体内生物相容性.

结论:

开发的宏分子对比剂显示出卓越的MRI对比增强和瘤向能力.
它的优良生物相容性和增强的瘤积累表明了早期瘤诊断的巨大潜力.
这种新型的CA代表了基于MRI的先进癌症检测和诊断的有希望的候选人.

更多相关视频

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

相关概念视频

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...